Last Updated : January 30, 2014
Details
FilesGeneric Name:
Alogliptin
Project Status:
Complete
Therapeutic Area:
Diabetes mellitus, type 2
Manufacturer:
Takeda Canada Inc.
Call for patient/clinician input open:
Brand Name:
Nesina
Project Line:
Reimbursement Review
Project Number:
SR0368-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Diabetes mellitus (Type 2)
Recommendation Type:
Do not list
Final Recommendation:
Files
Last Updated : January 30, 2014